Celon Pharma Sa · GPW:CLN
Celon Pharma Sa — Conference Presentation (April 2024)
16 slides from Celon Pharma Sa's conference presentation, Apr 24, 2024
Slide 1: Investor Presentation Y2023
INVESTOR PRESENTATION Y2023 WARSAW // 24.04.2024
Slide 2: Disclaimer
Neither this presentation (the “Presentation”, references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) nor any copy of it nor the information contained herein is being is
Slide 3: Financials
PHARMA FINANCIALS
Slide 4: Financial Outlook 2023 - Strong financial results in all business areas
Financial Outlook 2023 - Strong financial results in all business areas. Revenues of amounted to PLN 216.3 million compared to PLN 194.6 million in 2022. The increase in revenues by 11.2% mainly concerns the innovative segment +54.9%, and more specifically the increase refunds from ongoing R&D proje
Slide 5: Segment dynamics - Y2023/Y2022
Segment dynamics - Y2023/Y2022 All amounts in million PLN BRANDED GENERICS R&D TOTAL Revenues 200,0 Revenues INNOVATIVE PRODUCTS (R&D) 300,0 Revenues 216,6 49,5 200,0 194,6 167,0 162,6 32,0 150,0 100,0 FY23 FY22 FY23 FY22 FY23 FY22 Costs Costs 180,0 Costs 150,0 300,0 140,3 113,1 118,2 103,5 120,0 10
Slide 6: Group and Segment P&L Details for FY2023/FY2022
Group and Segment P&L Details for FY2023/ FY2022. Branded generics segment Innovation segment Total PLN Million FY2023 FY2022 FY2023 FY2022 FY2023 FY2022 Revenues from sales of medicines 164,4 159,3 0,0 0,0 164,4 159,3 Other revenues 2,6 0,7 0,0 0,0 2,6 0,7 Revenues from grants 0,0 0,0 49,5 32,0 49,
Slide 7: Balance sheet
Balance sheet. A. In FY2023 the Company maintains stable levels of CAPEX hence tangible assets record similar levels of nearly PLN 300m both as at 31Dec23 and 31Dec22. Major CAPEX relates to R&D projects. B. Equity stakes in other companies (Mabion) C. Decrease in cash in FY023 by PLN 50m of which P
Slide 8: Branded Generics
PHARMA BRANDED GENERICS
Slide 9: Revenues Y2022-YQ2023
Revenues Y2022-YQ2023 (MLN PLN) 216,5 200 194,5 Q4 2022 54,8 55,3 Q4 2023 +4,2 +0,2 +17,5 Q3 2022 45,0 48,8 Q3 2023 100 Q2 2022 52,8 68,4 Q2 2023 Q1 2022 41,9 43,9 Q1 2023 0 2022 Domestic Export Grants 2023 sales
Slide 10: Generics Drug Portfolio – share in total company sales in 2023
Generics Drug Portfolio – share in total company sales in 2023 111,3 mln PLN 32,6 mln PLN 7,7 mln PLN 4,9 mln PLN 3,9 mln PLN including export Salmex Ketrel Donepex Valzek Aromek + 2,5 mln + 1,1 mln PLN Y/Y PLN Y/Y Sales per product: Poland & abroad
Slide 11: Innovative Business
PHARMA ININIOW NENA BUSINESS
Slide 12: Clinical Pipeline
Clinical Pipeline Oncology Metabolic diseases Neuropsychiatry Inflamatory diseases Molecular Therapeutic Area Program Phase 1 Phase 2 Next Milestone Target FGFR To be complished Oncology CPL’110 Inhibitor Solid Tumors Q2 2024 NMDAR Ready to start Treatment-Resistant Depression Falkieri Agonist Phase
Slide 13: Diversified Platforms Drives Strong Early-Stage Pipeline
Diversified Platforms Drives Strong Early-Stage Pipeline Therapeutic Pre-clinical Program Molecular Target Research Next Milestone Area Development BsAbs targeting CPL’976 PD-1/PD-L1 - resistant Solid Tumors Tox results Q4 2024 tumors BsAbs targeting CPL’976- Oncology PD-1/PD-L1 - resistant Solid Tu
Slide 14: Publications & scientific conferences 2023
Publications & scientific conferences 2023 CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic - Publications Oct 2023 Oncology Agnieszka Bojko-Matuszek, Damian Kołakowski, Magdalena Bojko, Aleksandra Sowińska, Filip Mituła, Krzysztof Lace
Slide 15: Partnering Strategy 2023/2024
Partnering Strategy 2023/2024* Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q42024 FALKIERI FALKIERI CPL 280 CPL’ 280 CPL36 CPL’36 CPL116 CPL’116 CPL110 CPL’110 Metabolic diseases Oncology Neuropsychiatry Top line results Phase2 POC. Inflamatory diseases The implementation of the partnering strategy and
Slide 16: QA
QA